Conference Programme
Chair: Dinorah Friedmann-Morvinski, Senior Lecturer, Tel Aviv University, Israel
15:40 – 16:35
Opening keynote lecture: Principles of cell-based therapy
Nicholas Restifo, MD
Executive VP, Research, Lyell Immunopharma Inc., USA
16:35 – 16:55
Next generation approaches to improving CAR-T therapy
Jennifer Brogdon, PhD
Executive Director, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, USA
16:55 – 17:15
Gene engineering to Improve T cell function
Hans Stauss, MD, PhD
Director Institute of Immunity and Transplantation Co-Director Division of Infection and Immunity University College London Royal Free London NHS Foundation Trust, UK
17:20- 17: 40
E-Poster Session 1
HEMATOLOGICAL MALIGNANCIES
Chair: Tal Akriv, Tel Aviv University, Israel
17:20
CRISPR-CAS9 MEDIATED GENERATION OF CORD BLOOD TCRΑΒ-/- CD8+ T CELLS EXPRESSING RECOMBINANT WT1-TCR TO DECREASE RELAPSE IN ACUTE MYELOID LEUKEMIA PEDIATRIC PATIENTS
V. Lo Presti (Netherlands), E. Dunnebach (Netherlands), M. Plantinga (Netherlands), K. Jurgen (Netherlands), S. Nierkens (Netherlands), J.J. Boelens (USA), N. van Til (Netherlands)
17:27
REPROGRAMMED CAR T CELLS MAINTAIN METABOLIC POTENTIAL DURING RAPID EXPANSION AND SHOW INCREASED ANTI-TUMOR REACTIVITY
K. Mølgaard, Ö. Met, I.M. Svane (Denmark)
17:34
HEMATOPOIETIC MINOR HISTOCOMPATIBILITY ANTIGEN-SPECIFIC CD8+ T CELLS FOR ANTI-RELAPSE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
A. Pilunov, D. Romaniuk, S. Sheetikov, A. Khmelevskaya, A. Shmelev, N. Bykova, A. Shomuradova, D. Kiryukhin, D. Dianov, G. Efimov (Russia)
Chair: Claudia Rössig, Director, Department of Pediatric Hematology and Oncology, University Children´s Hospital Muenster, Germany
17:45 – 18:30
Keynote lecture: Advances in Engineered T Cell Therapy
Carl June, MD
Richard W. Vague Professor in Immunotherapy; Director, Center for Cellular Immunotherapies, Perelman School of Medicine Director, Parker Institute Cancer Immunotherapy; University of Pennsylvania USA
18:30 – 18:50
Ganglioside GD2-retargeted effector cells against solid cancers
Claudia Rössig, MD
Director, Department of Pediatric Hematology and Oncology, University Children´s Hospital Muenster, Germany
18:50 – 19:10
ACTR and BOXR: Addressing the challenges of T cell therapies in solid tumors
Seth Ettenberg, PhD
Chief Scientific Officer, UNUM Therapeutics, USA
19:10 – 19:30
Enhancing the efficacy of CAR T cells in solid tumours by promoting epitope spreading to target antigen negative tumours
Paul Beavis, PhD
Group Leader, Peter MacCallum Cancer Centre, Australia
Chair: Michael Hudecek, Director, CAR-T Programme University Hospital Würzburg, Germany
08:30 – 08:50
Targeting tumors infusing T cells genetically modified with non-viral Sleeping Beauty system
Laurence Cooper, MD, PhD
CEO, ZioPharm, USA
08:50 - 09:10
Sleeping Beauty-Engineered B Lymphocytes as Cellular Vehicles for Expression of Therapeutic Proteins
Scott McIvor, PhD
Chief Development Officer, Immusoft Corporation
Professor Genetics, Cell Biology, and Development, University of Minnesota, USA
09:10 - 09:30
New targets and technologies for CAR-T cells
Michael Hudecek, MD
Chair Hudecek Lab, Hospital of the University of Würzburg, Germany
09:30 - 09:50
Solupore®, a non-viral delivery technology for engineering immune cells
Susan Dunne, PhD
R&D Scientist, Avectas, Ireland
09:50 - 10:10
Advancing Adoptive Cellular Therapies Using Non-viral-based Engineering
Chris Mann, PhD
Director, Field Applications Scientists Team, MaxCyte Inc., USA
10:10 – 10:25
Abstract Oral Presentation
DEVELOPMENT OF CAR-T CELL THERAPY FOR B-ALL USING A POINT-OF-CARE APPROACH
L. Abdo, M. Viegas, L. Marques, P. Ferreira, L. Barros, L. Chicaybam, M. Bonamino (Brazil)
10:35 – 11:03
E-Poster Session 2
FIGHTING INFECTIONS AND AUTOIMMUNE DISEASES
Chair: Natalia Gritsenko, Tel Aviv University, Israel
10:35
DEVELOPING A CRISPR-CAS9 TOOL TO INACTIVATE THE GLUCOCORTICOID RECEPTOR AND BROADEN THE APPLICABILITY OF ANTIGEN-SPECIFIC T-CELL IMMUNOTHERAPY
M. Alvanou (Greece), C. Pantazi (Greece), K. Koukoulias (Greece), N. Psatha (USA), G. Tsiolas (Greece), I. Vallianou (Greece), M. Yiangou (Greece), A. Spyridonidis(Greece), K. Stamatopoulos (Greece), A. Anagnostopoulos (Greece), A. Makris (Greece), E. Yannaki (Greece), A. Papadopoulou (Greece)
10:42
ENGINEERING CELL-DERIVED NANOSCALE EXOSOMES FOR ANTI-INFLAMMATION AND IMMUNOTHERAPY
D. Levy, M. Do, A. Brown, B. Lu (USA)
10:49
DEEP-PRIMED IL-15 SUPERAGONIST IMPROVES ANTIVIRAL EFFICACY OF HIV-SPECIFIC CD8+ T-CELLS IN A HUMANIZED MOUSE MODEL
C. Mccann, E. Zale, A. Ward, T. Dilling, A. Danesh, E. Stevenson, T. Mota, T. Andresen, D. Jones, D. Irvine, R.B. Jones (USA)
10:56
CHARACTERIZATION OF MHC CLASS II-RESTRICTED T-CELL RECEPTORS FOR T-CELL THERAPY OF HBV INFECTION
S. Schreiber (Germany), M. Honz (Germany), M. Schiemann (Germany), A. Sette (USA), C. Zielinski (Germany), U. Protzer (Germany), K. Wisskirchen (Germany)
Chair: Andrew Sewell, Professor, Division of Infection and Immunity. Mechanisms of Immunity Theme Lead, Systems Immunity Research Institute, Cardiff University, UK
11:05 – 11:25
Designer T cells for immunotherapy of cancer
Wolfgang Uckert, PhD
Head of Department on Molecular Cell Biology and Gene Therapy at Max-Delbrück-Center for Molecular Medicine (MDC), Germany
11:25 – 11:45
Engineering of TCR-transgenic T cells by dual orthotopic TCR replacement
Dirk Busch, MD
Director at the Institute for Med. Microbiology, Immunology and Hygene Technical University of Munich, Germany
11:45 – 12:05
New TCRs and targets by dissection of successful TIL therapy
Andrew Sewell, PhD
Professor, Division of Infection and Immunity. Mechanisms of Immunity Theme Lead, Systems Immunity Research Institute, Cardiff University, UK
12:05 – 12:20
Abstract Oral Presentation
TCR/CAR GENE-MODIFIED ALLOGENEIC GAMMA/DELTA-T CELLS FOR THE TREATMENT OF HEMATOLOGICAL CANCERS
H. Fujiwara, S. Okumura, H. Miwa, Y. Akahori, Y. Miyahara, L. Wang, I. Tawara, T. Jo, Y. Tanaka, H. Ikeda, H. Shiku; Japan
12:20 – 12:35
Abstract Oral Presentation
ACTALLO®: USING TCR-ENGINEERED ALLOGENEIC GAMMA-DELTA T CELLS TO TREAT CANCER
M. Mata (USA), M. Kalra (USA), Z. Coughlin (USA), A. Nowicka (USA), N. Pawlowski (Germany), F. Schwoebel (Germany), L. Alten (Germany), S. Kuttruff-Coqui (Germany), S. Missel (Germany), N. Hilf (Germany), T. Weinschenk (Germany), H. Singh (USA), M. Dao (USA), Y. Bulliard (USA), S. Walter (USA)
12:45 – 13:49
E-Poster Session 3
CARS TARGETING SOLID TUMORS & CAR-T DESIGN AND OPTIMIZATION
Chair: Daniel Nataf, Tel Aviv University, Israel
12:45
DEVELOPMENT OF TCR-LIKE SCFV ZG CAR THAT SPECIFICALLY RECOGNIZES MAGE-A4230-239/HLA-A*02:01 COMPLEX
Y. Akahori, Y. Kato, Y. Miyahara, C. Amaike, L. Wang, K. Takuma, H. Fujiwara, H. Miwa, H. Ikeda, H. Shiku (Japan)
12:52
TARGETING MYELOID-DERIVED SUPPRESSOR CELLS AND IN SITU VACCINATION TO ENHANCE EFFICACY OF CAR T CELLS IN SOLID TUMORS
E. Conde-Gallastegi, J. Suarez, E. Elizalde, E. Vercher, U. Mancheño, N. Casares, T. Lozano, J.J. Lasarte, S. Hervás-Stubbs (Spain)
12:59
SUPPRESSION OF T CELLS THROUGH IN VITRO POLARISED MYELOID CELLS AS A BASIS FOR HIGH THROUGHPUT DRUG SCREENINGS TO IMPROVE IMMUNOTHERAPY OF SOLID CANCERS
J. Frosch, L. Gargiulo, C. Hanif Muflihah, J. Anderson (UK)
13:06
CAR-BASED IMMUNOTHERAPY OF EGFR-POSITIVE SOLID TUMOURS USING CYTOKINE-ACTIVATED PERIPHERAL BLOOD KILLER CELLS
O. Gavriliuc, R. Zogorean, F. Bojin, V. Paunescu (Romania)
13:13
POTENTIAL CANCER STEM CELL TARGETING CHIMERIC ANTIGEN RECEPTOR GENERATION WITH ANTIBODY VARIABLE REGION GENES IDENTIFIED BY IMMUNOGLOBULIN PROFILE ANALYSIS IN PATIENTS WITH MALIGNANT MELANOMA
B. Kotlan, S. Horvath, K. Eles, K. Czirbesz, G. Naszados, J. Olasz, E. Farkas, M. Ujhelyi, A. Szollar, A. Savolt, O. Csuka, M. Godeny, M. Kasler, G. Liszkay (Hungary)
13:20
OPTIMIZING CRISPR-CAS9 MEDIATED KNOCK-IN STRATEGY TO CREATE AN INDUCIBLE GENE EXPRESSION SYSTEM IN PRIMARY HUMAN T CELLS
Z. Odé, C.T. Petersen, G. Krenciute (USA)
13:27
IMPROVING CEA-TARGETED CAR-T CELL THERAPY FOR SOLID TUMOURS
W. Zheng, G. Kueberuwa, E. Cheadle, A. Armstrong (UK)
13:34
SHAPING FUNCTIONAL AVIDITY OF CAR-T CELLS: AFFINITY, AVIDITY AND ANTIGEN DENSITY THAT REGULATE RESPONSE
Yoram Reiter, PhD
Head Laboratory of Molecular Immunology and Cancer Immunotherapy,
Dean, Faculty of Biology, Technion-Israel Institute of Technology, Israel
Chair: Waseem Qasim, Professor of Cell and Gene Therapy, Institute of Child Health, UCL Consultant in Paediatric Immunology, Reader in Cell and Gene Therapy at Great Ormond Street Hospital for Children NHS Trust, UK
14:05 – 14:25
Challenges And Opportunities In Allogeneic Car-T Manufacturing At Different Stages Of Product Cycle
Ricardo Baptista, PhD
Director, Process and Analytical Development, Cellectis, France
14:25 – 14:45
Genome edited CAR T cells
Waseem Qasim, PhD
Professor of Cell and Gene Therapy, Institute of Child Health, UCL Consultant in Paediatric Immunology, Reader in Cell and Gene Therapy at Great Ormond Street Hospital for Children NHS Trust, UK
14:45 – 15:05
Combining innate immune targeting with adaptive immune power: Exploiting NKG2D for autologous and allogeneic CAR T cell therapy
Peggy Sotiropoulou, PhD
Director, Research & Development, Celyad, Belgium
15:05 – 15:25
Genetic engineering of off-the-shelf CAR T cells using ARCUS nucleases
Dan MacLeod, PhD
Director, Cell Therapy Discovery, Precision BioSciences Inc., USA
15:45 – 16:06
E-Poster Session 4
TCR TARGETING SOLID TUMORS & FIGHTING INFECTIONS AND AUTOIMMUNE DISEASES
Chair: Alessio Nahmad, Tel Aviv University, Israel
15:45
IDENTIFICATION OF A T CELL RECEPTOR SPECIFIC FOR GLYPICAN 3 FOR ADOPTIVE IMMUNOTHERAPY
S. Hervas-Stubbs, J. Gonzalez-Vaz, U. Mancheno, E. Elizalde, I. Tamayo, P. Sarobe (Spain)
15:52
A NOVEL TCR CLONING SYSTEM OF PEPTIDE-SPECIFIC T CELLS USING IMMUNOSPOT ARRAY ASSAY ON A CHIP (T-ISAAC) TECHNOLOGY
E. Kobayashi, T. Ozawa, H. Hamana, K. Shitaoka, A. Muraguchi, H. Kishi (Japan)
15:59
VACCINE ELICITATION OF HIV BROADLY NEUTRALIZING ANTIBODIES FROM ENGINEERED B CELLS
J. Voss (USA) , D. Huang (USA), J. Tran(USA), J. Abadajos (USA), A. Olson (USA), K. Saye (USA), T. Blane (USA), R. Fuller (USA), L. Couvrette (USA), M. Tenuta (USA), W. Li (USA), T. Schiffner (USA), E. Landais(USA), A. Gonzalez-Martin (Spain), D. Sok (USA), D. Burton (USA), W. Schief (USA), D. Nemazee (USA)
Chair: Sian Harding, Board Member of the British Society of Gene and Cell Therapy, Professor of Cardiac Pharmacology Director, BHF Cardiovascular Regenerative Medicine Centre Campus Director, Imperial Hammersmith and White City, NHLI, Imperial College London, UK
16:15 – 16:35
Engineering T-cells for therapy of inflammatory disorders
Andrew Scharenberg, MD
Professor, Department of Pediatrics University of Washington, and Attending Physician, Seattle Children’s Hospital Seattle, WA, United States Chief Scientific Officer, Casebia Therapeutics Cambridge, MA, USA
16:35 – 16:55
Engineering B cells as an evolving drug to fight HIV
Adi Barzel, PhD
President of the Israeli Society for Gene and Cell Therapy (ISGCT), ICLE Conference Chair, Senior lecturer at Tel-Aviv University, Israel
16:55 – 17:15
Engineered stem cell derived-lymphocytes for HIV therapy
Christopher Peterson, PhD
Research Assistant Professor, University of Washington
Staff Scientist, Fred Hutchinson Cancer Research Center, USA
17:15 – 17:35
Engineering B cells to protect against infection
Justin Taylor, PhD
Assistant Member, Immunology and Vaccine Development, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center Affiliate Assistant Professor, Departments of Immunology and Global Health, University of Washington, USA
17:35 – 17:50
Abstract Oral Presentation
``ONE SIZE FITS ALL`` STRATEGY FOR T CELL CORRECTION, SELECTION AND DEPLETION AS NEW TREATMENT FOR HIGM1 SYNDROME
V. Vavassori, E. Mercuri, G. Schiroli, G. Marcovecchio, M.C. Castiello, A. Annoni, L. Albano, C. Margulies, F. Buquicchio, C. Cotta Ramusino, A. Villa, L. Naldini, P. Genovese; Italy; USA
17:50 – 18:05
Abstract Oral Presentation
HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells
H. Hartweger, A. McGuire, M. Horning, J. Taylor J, P. Dosenovic, D. Yost, A. Gazumyan, M. Seaman S, L. Stamatatos, M. Jankovic, M. Nussenzweig C, USA
Chair: Michal Besser, Head of Laboratory Ella Lemelbaum Institute for Immuno Oncology Sheba Medical Center, Israel; Assistant Professor Dept. of Microbiology and Immunology School of Medicine, Tel Aviv University, Israel
08:30 – 08:50
Challenges of comparability for a commercial autologous cell therapy product
Simon Briggs, PhD
Senior Product Steward, Novartis Pharma Ag. Switzerland
08:50 – 09:05
From bench to bedside: Engineering of CAR T cells for research use and easy translation
Saskia Roesch, PhD
Global Product Manager, Miltenyi Biotec
09:05 – 09:20
Vector production and process development for CAR/TCR T cell therapies
Klaus Kühlcke, PhD
CEO, BioNTech IMFS GmbH, Germany
09:20 – 09:40
Engineering Regulatory T Cells for Autoimmunity, Inflammation & Transplantation
Jason Fontenot, PhD
Senior Vice President, Cell Therapy, Sangamo Therapeutics, France
09:50 – 10:18
E-Poster Session 5
NEW HORIZONS IN LYMPHOCYTE ENGINEERING
Chair: Inbal Reuveni, Tel Aviv University, Israel
09:50
IN VIVO THYMOCYTE ENGINEERING
N. Gritsenko, M. Fried, C. Pundak-Mintz, Y. Zilberstein, I. Dotan, A. Zoaby, A. Globerson Levin, A. Barzel (Israel)
09:57
ADVANCING CAR T CELL THERAPY UTILIZING IN SITU TRANSDUCTION
G. Horn (Israel), A. Najjar (USA), A. Globerson Levin (Israel), T. Waks (Israel), Z. Eshhar (Israel)
10:04
ENGINEERING B CELLS FOR A REGULATED, IMMUNODOMINANT AND EVOLVING TREATMENT FOR HIV INFECTIONS
A. Nahmad, T. Akriv, D. Nataf, M. Fried, I. Dotan, Y. Wine, I. Benhar, A. Barzel (Israel)
10:11
TOWARDS SAFE AND EFFICIENT DELIVERY OF MRNA AND CRISPR-CAS9 COMPLEXES IN T CELLS BY VAPOR NANOBUBBLE PHOTOPORATION
L. Raes, S. Stremersch, J. Fraire, T. Brans, G. Goetgeluk, J. Van Hoeck, R. Xiong, B. Vandekerckhove, S. De Smedt C., K. Raemdonck, K. Braeckmans (Belgium)
Chair: Yaron Carmi, Senior Lecturer, Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Israel
10:20 – 10:40
A new approach to cancer immunotherapy based on a novel cytotoxic CD4+ T Cell
Yaron Carmi, PhD
Senior Lecturer, Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Israel
10:40 – 11:00
T-cell targeted lentiviral vectors for the generation of CAR T Cells
Christian Buchholz, PhD
Head of Molecular Biotechnology and Gene Therapy Paul-Ehrlich-Institute, Germany
11:00 – 11:20
Fine tuning cellular engineering for cancer using gamma delta lymphocytes
John Anderson, PhD
GOSHCC Professor of Experimental Paediatric Oncology Honorary Consultant Oncologist UCL Great Ormond Street Institute of Child Health, UK
11:20 – 11:35
Abstract Oral Presentation
TRUCKs: the fourth generation of CAR T cells for advanced adoptive cell therapy
H. Abken, Germany
11:35 – 11:50
Abstract Oral Presentation
UNICAR T-CELLS RETARGETED VIA SHORT-LIVED AND EXTENDED HALF-LIFE TARGET MODULES – A COMBINED APPROACH FOR CANCER IMMUNOTHERAPY
L. Loureiro, A. Feldmann, R. Bergmann, N. Berndt, A. Hoffmann, N. Mitwasi, J. Jureczek, S. Koristka, M. Bachmann, C. Arndt, Germany
11:50 – 12:05
Abstract Oral Presentation
GATED TARGETING WITH A NOVEL SWITCHABLE CAR PLATFORM TECHNOLOGY
A. Feldmann, A. Hoffmann, E. Kittel-Boselli, R. Bergmann, S. Koristka, C. Arndt, L. Loureiro, N. Berndt, M. Bachmann, Germany
12:05 – 12:20
Abstract Oral Presentation
AvidCARs – a novel platform for integration of multiple input signals by one CAR molecule
B. Salzer, C.U. Brey, C. Schüller, M. Schöber, E. Lobner, O. Dushek, W. Holter, M.W. Traxlmayr, M. Lehner, Austria; UK
12:30-13:12
E-Poster Session 6
GENOME EDITING FOR ALLOGENEIC ACT & OTHER
Chair: Yuval Raviv, Tel Aviv University, Israel
12:30
THE TARGETED KNOCKDOWN OF CD3Ζ BY SHRNA AS A PLATFORM TO DEVELOP ALLOGENEIC CAR T CELL THERAPY
S. Raitano, A. Michaux, S. Bornschein, J. Bolsée, S. Lenger, H. Machado, P. Sotiropoulou, D. Gilham (Belgium, USA)
12:37
SYNTHETIC SURFACES FOR ENHANCEMENT OF T-CELL THERAPIES
S. Adutler-Lieber, N. Friedman, B. Geiger (Israel)
12:44
RECEPTORS PROVIDING TUMOUR ANTIGEN RESTRICTED COSTIMULATION ENHANCE T-CELL ACTIVITY FOR ADOPTIVE T-CELL THERAPY
M. Sykorova, M. Kalaitsidou, M. Le Brocq, A. Patel, T. Katopodi, R. Hawkins, G. Kueberuwa, J. Bridgeman (UK)
12:51
NANOSTRAW-MEDIATED DELIVERY ENABLES FAST AND EFFICIENT DELIVERY OF MOLECULAR CARGO TO HARD-TO-TRANSFECT MAMMALIAN CELLS IN A NON-PERTURBATIVE FASHION WHILE MAINTAINING HIGH VIABILITY
S. Johnson, S. Leal-Ortiz, M. Hjort, H. Vossfeldt, R. Swoboda, S. Boyatzis (USA)
12:58
THE ROLE OF THE EXTRACELLULAR CD28 DOMAIN IN CAR T CELLS: MONOMERISATION AND TRUNCATION IMPACT THE ACTIVATION OF CD28 CAR T CELLS
A. Kilgallon, R. Hawkins, E. Cheadle, J. Bridgeman, A. Armstrong, D. Gilham, A. Schutt, M. Kalaitsidou, G. Kueberuwa (UK)
13:05
MELANOMA-INFILTRATING DENDRITIC CELLS ARE REQUIRED FOR LICENSING THE CYTOTOXIC ACTIVITY OF CD8+ T CELLS IN SITU
N. Santana-Magal, L. Farhat-Younis, D. Rasoulouniriana, A. Gutwillig, L. Tal, P. Rider, Y. Carmi (Israel)
Chair: Adi Barzel, President of the Israeli Society for Gene and Cell Therapy (ISGCT), ICLE Conference Chair, Senior lecturer at Tel-Aviv University, Israel
13:50 – 14:35
Keynote lecture: Novel approaches to engineering T cells for cancer
Stanley Riddell, MD
Director, Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Professor, Department of Medicine at the University of Washington USA
14:35 – 15:20
Panel Discussion: Where are we headed from here?
Moderator: Adi Barzel, PhD
President of the Israeli Society for Gene and Cell Therapy (ISGCT), ICLE Conference Chair, Senior lecturer at Tel-Aviv University, Israel
Stanley Riddell, MD
Director, Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Professor, Department of Medicine at the University of Washington USA
Jennifer Brogdon, PhD
Executive Director, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, USA
Dirk Busch, MD
Director at the Institute for Med. Microbiology, Immunology and Hygene Technical University of Munich, Germany
Closing Address
